Nomides capsules 75 mg 10 pcs ➤ instructions for use
The drug oseltamivir is taken orally, regardless of meals or with meals. Treatment The drug should be started no later than 2 days after the development of symptoms of the disease. Adults and adolescents ≥ 12 years of age The recommended daily dose is 150 mg. The drug is prescribed in a dose of 75 mg (one capsule 75 mg or one capsule 30 mg + one capsule 45 mg) 2 times a day orally for 5 days. Children weighing more than 40 kg or aged ≥ 8 years Children who can swallow capsules can also be treated by taking 75 mg (one 75 mg capsule or one 30 mg capsule + one 45 mg capsule) twice daily within 5 days. Children aged ≥ 1 year The recommended dosage regimen for oseltamivir capsules is 30 and 45 mg. Body weight Recommended dose for 5 days ≤15 kg: 30 mg twice a day >15-23 kg: 45 mg twice a day >23-40 kg: 60 mg twice a day Prevention The drug should be started no later than 2 days after contact with patients. Adults and adolescents aged ≥ 12 years 75 mg (one 75 mg capsule or one 30 mg capsule + one 45 mg capsule) once daily orally for at least 10 days after contact with the patient. During a seasonal flu epidemic - 75 mg 1 time per day for 6 weeks. The preventive effect lasts as long as the drug is taken. Children weighing more than 40 kg or aged ≥ 8 years Children who can swallow capsules can also receive preventive therapy by taking 75 mg (one 75 mg capsule or one 30 mg capsule + one 45 mg capsule) once daily within 10 days. Children aged ≥ 1 year The recommended dosage regimen for oseltamivir capsules is 30 and 45 mg. The recommended dosage regimen for oseltamivir capsules is 30 and 45 mg. Body weight Recommended dose for 10 days ≤15 kg: 30 mg once daily >15-23 kg: 45 mg once daily >23-40 kg: 60 mg once daily Dosing in special cases Patients with impaired function kidneys: Treatment Patients with creatinine clearance more than 60 ml/min do not require dose adjustment. In patients with a creatinine clearance of 30 to 60 mL/min, the dose of oseltamivir should be reduced to 30 mg twice daily for 5 days. In patients with a creatinine clearance of 10 to 30 ml/min, the dose of oseltamivir should be reduced to 30 mg once daily for 5 days. For patients on chronic hemodialysis, oseltamivir at an initial dose of 30 mg can be taken before starting dialysis if flu-like symptoms appear within 48 hours between dialysis sessions. To maintain plasma concentrations at therapeutic levels, oseltamivir should be taken 30 mg after each dialysis session. For patients on peritoneal dialysis, oseltamivir should be taken at an initial dose of 30 mg before starting dialysis, then 30 mg every 5 days. The pharmacokinetics of oseltamivir in patients with end-stage chronic renal failure (with creatinine clearance ≤10 ml/min) not on dialysis have not been studied. In this regard, there are no dosage recommendations for this group of patients. Prevention Patients with creatinine clearance more than 60 ml/min do not require dose adjustment. In patients with a creatinine clearance of 30 to 60 ml/min, the dose of oseltamivir should be reduced to 30 mg once daily. In patients with creatinine clearance from 10 to 30 ml/min, it is recommended to reduce the dose of oseltamivir to 30 mg every other day. For patients on chronic hemodialysis, oseltamivir at an initial dose of 30 mg can be taken before starting dialysis. To maintain plasma concentrations at therapeutic levels, oseltamivir should be taken 30 mg after each subsequent odd-numbered dialysis session. For patients on peritoneal dialysis, oseltamivir should be taken at an initial dose of 30 mg before starting dialysis, then 30 mg every 7 days. The pharmacokinetics of oseltamivir in patients with end-stage chronic renal failure (with creatinine clearance less than 10 ml/min) not on dialysis have not been studied. In this regard, there are no dosage recommendations for this group of patients. Patients with impaired liver function No dose adjustment is required for the treatment and prevention of influenza in patients with mild to moderate hepatic impairment. The safety and pharmacokinetics of oseltamivir in patients with severe hepatic impairment have not been studied. Elderly and senile patients No dose adjustment is required for the prevention or treatment of influenza. Patients with weakened immune systems (after transplantation). For seasonal prophylaxis of influenza in immunocompromised patients aged ≥1 year - for 12 weeks, no dose adjustment is required.
Extemporaneous preparation of Nomides® suspension from capsules
In cases where adults, adolescents and children have difficulty swallowing capsules or there are signs of "aging" of the capsules, it is necessary to open the capsule and pour its contents into a small amount (maximum 1 teaspoon) of a suitable sweetened food product (normal chocolate syrup). sugar or unsweetened, honey, light brown sugar or table sugar dissolved in water, sweet dessert, sweetened condensed milk, applesauce or yogurt) to cover up the bitter taste. The mixture must be mixed thoroughly and given to the patient as a whole. The mixture should be swallowed immediately after preparation.
Capsules 75 mg
If patients require a dose of 75 mg , the following instructions should be followed:
1. Holding one Nomides® 75 mg capsule over a small container, carefully open the capsule and pour the powder into the container.
2. Add a small amount (no more than 1 teaspoon) of a suitable sweetened food (to cover the bitter taste) and mix well.
3. Mix the mixture thoroughly and drink it immediately after preparation. If there is a small amount of mixture left in the container, you should rinse the container with a small amount of water and drink the remaining mixture.
If patients require doses of 30-60 mg , the following instructions should be followed for proper dosing:
1. Holding one Nomides® 75 mg capsule over a small container, carefully open the capsule and pour the powder into the container.
2. Add 5 ml of water to the powder using a syringe with marks indicating the amount of liquid collected. Mix thoroughly for 2 minutes.
3. Draw the required amount of mixture into the syringe from the container according to the following table.
Body weight / Recommended dose / Amount of Nomides® mixture per 1 dose
≤15 kg / 30 mg / 2 ml
>15-23 kg / 45 mg / 3 ml
>23-40 kg / 60 mg / 4 ml
There is no need to collect undissolved white powder as it is an inactive filler. By pressing the plunger of the syringe, inject all its contents into the second container. Any remaining unused mixture should be discarded.
4. In a second container, add a small amount (no more than 1 teaspoon) of a suitable sweetened food to cover the bitter taste and mix well.
5. Mix the mixture thoroughly and drink it immediately after preparation. If there is a small amount of mixture left in the container, you should rinse the container with a small amount of water and drink the remaining mixture.
This procedure should be repeated before each dose of the drug.
